CONAVI MEDICAL CORP (CNVI.CA) Stock News

Conavi Medical Announces Uplisting to OTCQB Venture Market

- Expected to enhance visibility and access to U.S. investors - Trading to commence on March 6, 2025 TORONTO, March 06, 2025 (GLOBE NEWSWIRE)...

Conavi Medical Highly Encouraged by New U.S. Intracoronary Guidelines

– IVUS and OCT cited as playing essential and complementary roles, validating Novasight’s unique hybrid imaging capability – Guidelines constitute...

Conavi Medical Reports Fiscal Q1 2025 Interim Financial Results and Operational Highlights

– Completed first quarter as a public company and raised $10.6 mil CAD concurrent with listing – Next-generation Novasight design freeze completed on...

Conavi Medical Retains BND Projects Inc. for Corporate Development Services

TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Corporation”), a commercial stage medical device company...

Conavi Medical Corp. Announces Proposed Public Offering of Units

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, Jan. 30, 2025 (GLOBE NEWSWIRE) --...

Conavi Medical Provides Shareholder Update and 2025 Outlook

- U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026- Evolving medical...

Conavi Medical and Minnetronix Medical Publish In-Depth Collaboration Review

TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical...

Conavi Medical Announces Grant of Stock Options

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”) announced that its board of directors...

Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights

– Completed US$7.7 million financing and reverse takeover to take Company public – Chinese partner achieved regulatory approval, setting stage for royalty...

Conavi Medical to Participate in the MedInvest MedTech, AI & Digital Health Conference

– Marks first time as a public company that Conavi is presenting at an investor event – – Live webcast presentation on Wednesday, December 11ᵗʰ at...

China's NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP

– Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the promissory note owed by it to...

JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies

– Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and co-registered imaging of...

Conavi Medical Corp. Engages ICP Securities Inc. for Automated Market Making Services

TORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- CONAVI MEDICAL CORP. (TSXV: CNVI) (“CONAVI MEDICAL” or the “Company”), a commercial stage company focused on...

Conavi Medical Corp. Commences Trading on TSX-V Under Symbol “CNVI”

TORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (formerly, “Titan Medical Inc.”) (“Conavi” or the “Company”) (TSXV: CNVI) is pleased to announce that, pursuant to its press releases dated September 30, 2024 and October 11, 2024, the Company’s common shares (“Common Shares”) have been voluntarily delisted from the Toronto Stock Exchange, effective as of close of markets on October 15, 2024, and will commence trading at the market open today on the TSX Venture Exchange (the “TSXV”) under the new symbol “CNVI”. The Company has been classified by the TSXV as a Tier 2 Technology issuer.

Conavi Medical Corp. Commences Trading on TSX-V Under Symbol “CNVI”